Adam Boxer

Prof. Adam Boxer is Professor of Neurology and the Vera and John Graziadio Scholar in Alzheimer’s Disease Research at UCSF, where he directs the Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. He was the lead principle investigator of the first US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. He is principal Investigator of the NIH-funded, North American rare disease clinical research consortium, entitled Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), which is dedicated to preparing for clinical trials in PSP and other FTLD-spectrum disorders.